Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Kairos Pharma reported interim safety data from its Phase 1 trial of ENV-105 (carotuximab) in combination with AstraZeneca's Tagrisso, showing zero Grade 3+ toxicities in 13 patients. The clean safety profile supports continued progression toward an efficacy readout for ENV-105, which aims to reverse resistance to osimertinib in EGFR-mutated lung cancer.
Key figures
- Drug Name
- ENV-105 (carotuximab)
- Phase Of Trial
- Phase 1
- Market cagr
- 10.5%
- Market value usd
- 10 billion
- Patients treated
- 13
- Market projection 2030 usd
- 13 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.